

Audit & Risk Assurance Committee Meeting (incl review of final annual report and accounts)



Agenda

Date 23 June 2026
Time 09:00 - 13:00
Location Microsoft Teams Meeting; HDD Picton - Dolau Cothi
Title Audit & Risk Assurance Committee Meeting (incl review of final annual report and accounts)
—

1 - 1 Introductions

09:00,

1.1 - Apologies

For information

09:00, Rhodri Evans (Hywel Dda UHB - Independent Member)

1.2 - Declaration of Interests

For information

09:00, All

[HDdUHB Register of Board Members Interests 2026-27](#)

2 - Governance

09:00,

2.1 - Minutes of the Meeting held on 14 April 2026

For approval

09:00, Rhodri Evans (Hywel Dda UHB - Independent Member)

2.2 - Table of Actions

For assurance

09:00, Rhodri Evans (Hywel Dda UHB - Independent Member)

2.3 - Matters Arising not on Agenda

For discussion

09:05, Rhodri Evans (Hywel Dda UHB - Independent Member)

2.4 - Escalation Status Update Report

For assurance

09:05, Philip Kloer (Hywel Dda UHB - Chief Executive), Lee Davies (Hywel Dda UHB - Executive Director of Strategy and Planning), Shaun Ayres (Hywel Dda UHB - Director of Delivery)

2.5 - Committee Self-Assessment

For assurance

09:20, Joanne Wilson (Hywel Dda UHB - Director of Corporate Governance/Board Secretary)

2.6 - Annual Review of Committee Terms of Reference

For approval

09:25, Joanne Wilson (Hywel Dda UHB - Director of Corporate Governance/Board Secretary)

2.7 - All Wales NHS Audit Committee Chairs' Meeting Update

For information

09:30, Rhodri Evans (Hywel Dda UHB - Independent Member)

3 - Audit Wales

09:35,

3.1 - Audit Wales Update Report

For assurance

09:35, Anne Beegan, Urvisha Perez

3.2 - Review of Radiology Services

For assurance

09:40, Anne Beegan, Urvisha Perez, David Murphy, Andrew Carruthers (Hywel Dda UHB - Chief Operating Officer), Sara Quarrie (Hywel Dda UHB - Service Director for Allied Health Professions and Health Sciences)

4 - NWSSP – Audit and Assurance Services - Internal Audit

09:55,

4.1 - Internal Audit Plan Progress Report

For assurance

09:55, James Johns (NWSSP - Internal Audit)

4.2 - Progress Update on Operational Governance Arrangements Internal Audit

*For
assurance*

10:00, Andrew Carruthers (Hywel Dda UHB - Chief Operating Officer), Gareth Cottrell (Hywel Dda UHB - Deputy Chief Operating Officer)

4.3 - BREAK

10:15,

4.4 - GP Out of Hours (Limited Assurance)

For assurance

10:25, James Johns (NWSSP - Internal Audit), Andrew Carruthers (Hywel Dda UHB - Chief Operating Officer), Rhian Bond (Hywel Dda UHB - Assistant Director of Primary Care)

4.5 - Commissioning Third Sector (Reasonable Assurance)

For assurance

10:45, James Johns (NWSSP - Internal Audit), Andrew Carruthers (Hywel Dda UHB - Chief Operating Officer), Peter Skitt (Hywel Dda UHB - Clinical Care Group Service Director - Community & Integrated Medicine), Keith Jones (Hywel Dda UHB - Director of Operational Planning & Performance)

**4.6 - Regional Joint Committee Governance Arrangements
(Advisory Report)**

*For
assurance*

10:55, James Johns (NWSSP - Internal Audit), Joanne Wilson (Hywel Dda UHB - Director of Corporate Governance/Board Secretary)

4.7 - Infection Prevention & Control (Limited Assurance)

For assurance

11:00, James Johns (NWSSP - Internal Audit), Sharon Daniel (Hywel Dda UHB - Executive Director of Nursing, Quality & Patient Experience), Rebecca Richards (Hywel Dda UHB - Head of infection prevention)

4.8 - Medical Workforce Stabilisation (Reasonable Assurance)

For assurance

11:20, James Johns (NWSSP - Internal Audit), Mark Henwood (Hywel Dda UHB - Executive Medical Director), Carly Hill (Hywel Dda UHB - Assistant Director)

4.9 - High Cost Drugs (Limited Assurance)

For assurance

11:30, James Johns (NWSSP - Internal Audit), Mark Henwood (Hywel Dda UHB - Executive Medical Director), Huw Thomas (Hywel Dda UHB - Director of Finance), Dilesh Khandhia (Hywel Dda UHB - Associate Clinical Director of Pharmacy & Medicines Management)

4.10 - WellSky System (Advisory Report)

For assurance

11:50, James Johns (NWSSP - Internal Audit), Huw Thomas (Hywel Dda UHB - Director of Finance)

4.11 - Follow Up and Action Implementation Review (Reasonable Assurance)

*For
assurance*

11:55, James Johns (NWSSP - Internal Audit), Joanne Wilson (Hywel Dda UHB - Director of Corporate Governance/Board Secretary)

4.12 - Head of Internal Audit Opinion & Annual Report 2025/26

For discussion

12:00, James Johns (NWSSP - Internal Audit)

5 - Financial Focus

12:10,

5.1 - Financial Assurance Report

For approval

12:10, Huw Thomas (Hywel Dda UHB - Director of Finance)

5.2 - Counter Fraud Update

For information

12:15, Benjamin Rees (Hywel Dda UHB - Local Counter Fraud Specialist)

6 - Assurance and Risk

12:20,

6.1 - External Recommendations and Welsh Health Circulars Assurance Report

For assurance

12:20, Joanne Wilson (Hywel Dda UHB - Director of Corporate Governance/Board Secretary)

7 - Year-end Governance

12:25,

7.1 - HDdUHB Annual Report 2025/26

For approval

12:25, Philip Kloer (Hywel Dda UHB - Chief Executive)

7.2 - Final Accounts for 2025/26

For approval

12:40, Huw Thomas (Hywel Dda UHB - Director of Finance), Rhian Davies (Hywel Dda Health Board - Assistant Director of Finance - Financial Planning & Statutory Reporting), Timothy John (Hywel Dda UHB - Head of Accounting & Statutory Reporting)

7.3 - Audit Wales ISA 260 and Letter of Representation

For assurance

12:50, Huw Thomas (Hywel Dda UHB - Director of Finance), Rhian Davies (Hywel Dda Health Board - Assistant Director of Finance - Financial Planning & Statutory Reporting, Timothy John (Hywel Dda UHB - Head of Accounting & Statutory Reporting)

8 - For Information

13:00,

8.1 - ARAC Workplan 2026/27

For information

13:00,

9 - Any Other Business

13:00,

10 - Review of Meeting

13:00,

10.1 - Matters and Risks for Escalation to the Board

For discussion

13:00,

11 - Date and Time of Next Meeting

13:00,

9.30am, 13 August 2026

|| - In-Committee Session

13:00,

In accordance with the Committee's Terms of Reference, which permit the Committee to operate an in-committee function for the consideration of sensitive and/or confidential information, the next part of the meeting will be held in private session. Attendance will be restricted to Committee Members and those individuals (or their nominated deputies) identified in the Terms of Reference.

This session will consider the following items:

1. Counter Fraud Investigations

A summary of matters considered will be reported to the next appropriate Committee meeting.